Oprozomib in patients with newly diagnosed multiple myeloma

被引：16
|
作者：
Hari, Parameswaran [1 ]
Matous, Jeffrey V. [2 ]
Voorhees, Peter M. [3 ]
Shain, Kenneth H. [4 ]
Obreja, Mihaela [5 ]
Frye, John [5 ]
Fujii, Hisaki [5 ]
Jakubowiak, Andrzej J. [6 ]
Rossi, Davide [7 ]
Sonneveld, Pieter [8 ]
机构：
[1] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[2] Colorado Blood Canc Inst, Denver, CO USA
[3] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[5] Amgen Inc, Thousand Oaks, CA 91320 USA
[6] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[7] Univ Piemonte Orientale, Novara, Italy
[8] Erasmus MC Canc Inst, Rotterdam, Netherlands
来源：
BLOOD CANCER JOURNAL | 2019年 / 9卷 / 9期
关键词：
DEXAMETHASONE; CARFILZOMIB; CYCLOPHOSPHAMIDE; LENALIDOMIDE; MULTICENTER;
D O I：
10.1038/s41408-019-0232-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Treatment of transplant-eligible patients with newly diagnosed multiple myeloma
    Nakaseko, Chiaki
    ANNALS OF ONCOLOGY, 2017, 28
  • [42] Treatment Satisfaction and Burden of Illness in Patients with Newly Diagnosed Multiple Myeloma
    Robert M. Rifkin
    Jill A. Bell
    Pronabesh DasMahapatra
    Michael Hoole
    Maria Lowe
    Chris Curran
    Scott Campbell
    Peijie Hou
    Dorothy Romanus
    PharmacoEconomics - Open, 2020, 4 : 473 - 483
  • [43] Infectious Complications and Their Relationship with Mortality in Patients Newly Diagnosed with Multiple Myeloma
    Luis Ontiveros, Juan Luis
    Rajme-Lopez, Sandra
    Orozco, Alfonso
    Rodriguez-Rodriguez, Sergio
    Riviello-Goya, Santiago
    Seidman-Sorsby, Alec
    Aguayo, Alvaro
    Martinez-Banos, Deborah
    BLOOD, 2022, 140 : 12508 - 12509
  • [44] The Clinical Relevance of Selected Cytokines in Newly Diagnosed Multiple Myeloma Patients
    Mielnik, Michal
    Szudy-Szczyrek, Aneta
    Homa-Mlak, Iwona
    Mlak, Radoslaw
    Podgajna-Mielnik, Martyna
    Goracy, Aneta
    Malecka-Massalska, Teresa
    Hus, Marek
    BIOMEDICINES, 2023, 11 (11)
  • [45] Frailty and initial treatment intensity in patients newly diagnosed with multiple myeloma
    DuMontier, Clark
    La, Jennifer
    Bihn, John
    Corrigan, June
    Yilidrim, Cenk
    Dharne, Mayuri
    Hassan, Hamza
    Yellapragada, Sarvari
    Abel, Gregory
    Gaziano, J. Michael
    Do, Nhan
    Brophy, Mary
    Kim, Dae
    Munshi, Nikhil
    Fillmore, Nathanael
    Driver, Jane
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S24 - S25
  • [46] How should we treat newly diagnosed multiple myeloma patients?
    Mateos, Maria-Victoria
    San Miguel, Jesus F.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2013, : 488 - 495
  • [47] The Significance of Inflammatory Markers in the Prognosis of Newly Diagnosed Multiple Myeloma Patients
    Gui, Lin
    Wang, Fei
    Shi, Jinning
    Chen, Baoan
    BLOOD, 2020, 136
  • [48] Underweight as a risk factor of mortality in patients with newly diagnosed multiple myeloma
    Chun-Kuang Tsai
    Chiu-Mei Yeh
    Te-Lin Hsu
    Chia-Ju Li
    Chian Tin
    Liang-Tsai Hsiao
    Yao-Chung Liu
    Hao-Yuan Wang
    Po-Shen Ko
    Po-Min Chen
    Jin-Hwang Liu
    Jyh-Pyng Gau
    Chia-Jen Liu
    Supportive Care in Cancer, 2021, 29 : 3991 - 3999
  • [49] Treatment of Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients
    Shaji Kumar
    Current Hematologic Malignancy Reports, 2011, 6 : 104 - 112
  • [50] Risk Factors for Renal Failure in Patients with Newly Diagnosed Multiple Myeloma
    Fuentes-Lacouture, Maria C.
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S28 - S29
12345